AI-Accelerated drug discovery needs collaboration and the infrastructure to support it

With research budgets under pressure and development costs rising fast, life sciences organisations are looking for ways to do more with their existing data and be interoperable with newly generated data.

At the same time, large language models (LLMs) and advanced AI systems promise faster insights, but only if they can be trained on large, accurate, and up-to-date datasets.

That’s where co-location data centres and interconnectivity come in.

Duplication to discovery

Much of the data being generated across healthcare and life sciences today is trapped.

Whether due to strict data protection laws or being unidentifiable, valuable information is often stored in siloed systems, inaccessible even to potential collaborators within the same industry.

The result is an unnecessary duplication of trials, wasted time and resources, and lost opportunities to accelerate discoveries.

The shift to colocation data centres offering neutral, highly secure facilities where multiple organisations can host and connect their data infrastructure, offers a way forward.

These centres don’t just store data, they facilitate high-speed, compliant, and secure data exchange between organisations, offering a ready-made environment for secure collaboration.

A path to shared progress

Pharmaceutical and biotech companies have long been cautious about sharing data, particularly with competitors. But the economics of drug development are changing.

It can now cost between $1 billion and $2.6 billion to bring a new drug to market, often for just 5-12 years of exclusivity before generics arrive.

This has triggered a shift toward “coopetition” where the mutual benefit of speed and innovation into new therapeutic areas outweighs the traditional desire for secrecy.

And when AI is part of the picture, sharing becomes even more valuable. AI models improve exponentially when trained on more comprehensive datasets.

Co-located environments allow life sciences companies to do this without compromising privacy or control, creating a foundation for smarter, faster research.

Enabling responsible innovation

Data sharing in life sciences is rightly subject to strict governance. That’s why data centres have evolved to support this need.

Providers like Equinix maintain specialised compliance teams to ensure alignment with regulations such as the General Data Protection Regulation (GDPR) and the emerging European Health Data Space (EHDS).

This makes it possible for organisations to collaborate while maintaining full control of their data and upholding patient privacy.

From MRI to market

The promise of shared data extends beyond research labs.

For example, MRI scans stored in co-located environments could be used not just for a single diagnosis but as part of broader datasets powering AI models capable of spotting early patterns of disease across populations.

Human experts would still validate the results, but the time to diagnosis could be drastically reduced.

When data is pooled and platforms are in place to make sense of it, researchers benefit from faster workflows, faster treatments, reduced costs and shorter development cycles.

Patients will ultimately benefit the most from earlier diagnoses to access to life-saving therapies delivered years ahead of previous timelines.

Looking ahead

At a time when healthcare and life sciences face growing complexity and shrinking margins, shared infrastructure offers a way to amplify the value of every dataset, every researcher and every investment.

AI will no doubt be a defining tool in the future of drug discovery, but it will be collaboration, enabled by the right data architecture, that unlocks its full potential.

It’s time to move from working in silos to building an interconnected research ecosystem that’s both fast and compliant.